Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zosano Pharma Corporation ZSANQ

Healthcare Biotechnology
Zosano Pharma Corp is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Zosano Pharma Corp is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K... see more

Recent & Breaking News (EXPM:ZSANQ)

Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update

GlobeNewswire May 8, 2018

Zosano Appoints Kenneth Greathouse to Board of Directors

GlobeNewswire October 4, 2017

Zosano Provides Patent Application Update

GlobeNewswire September 26, 2017

Zosano Presents Data from ZOTRIP Study at International Headache Society

GlobeNewswire September 13, 2017

Technical Snapshots for These Biotech Stocks -- ZIOPHARM Oncology, Zosano Pharma, Juno Therapeutics, and Lexicon Pharma

PR Newswire September 7, 2017

Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly Achieving Therapeutic Concentrations of Triptans for Treatment of Migraines”

GlobeNewswire August 28, 2017

Investor Network: Zosano Pharma Corp. to Host Earnings Call

Accesswire August 10, 2017

Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results and Provide Operational Update

GlobeNewswire August 2, 2017

Zosano Announces Publication of Positive Phase 1 Data of Zolmitriptan Delivery In Future Medicine’s Pain Management Journal

GlobeNewswire July 31, 2017

Zosano Pharma Announces Outcome of End of Phase 2 Meetings with FDA

GlobeNewswire June 26, 2017

Zosano Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire June 14, 2017

Zosano Presents Additional Data from ZOTRIP Study at American Headache Society, Demonstrating Positive Results for Pain Freedom and Sustained Pain Freedom

GlobeNewswire June 12, 2017

Zosano to Present Migraine Data at Three Industry-Leading Conferences

GlobeNewswire June 1, 2017

Biotech Stocks Under Scanner -- Bioverativ, Zosano Pharma, MannKind, and Ocera Therapeutics

PR Newswire May 10, 2017

Zosano Reports First Quarter 2017 Financial Results and Announces Management Changes

GlobeNewswire May 9, 2017

Investor Network: Zosano Pharma Corp. to Host Earnings Call

Accesswire May 9, 2017

Zosano Pharma to Host Conference Call on First Quarter 2017 Financial Results and Provide Operational Update

GlobeNewswire May 8, 2017

Zosano Announces Closing of Public Offering of Common Stock and Exercise of Underwriters’ Over-Allotment Option

GlobeNewswire March 22, 2017

Zosano Announces Pricing of Public Offering of Common Stock

GlobeNewswire March 17, 2017

12 Biggest Mid-Day Losers For Monday

Benzinga.com  March 13, 2017